Ulcerative Colitis stem cell therapy — your questions answered (2026)

About stem cell therapy for Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon and rectum. Mesenchymal stem cell research in UC explores immunomodulatory and tissue-repair mechanisms, but this remains investigational. Darvadstrocel, an MSC product formerly authorised in the EU for complex perianal Crohn's fistulae, had its marketing authorisation withdrawn in December 2024; that former indication did not establish efficacy for ulcerative colitis.

The evidence for Ulcerative Colitis

Evidence for systemic MSC or other cell treatment of ulcerative colitis remains early and heterogeneous. Studies vary by product, route, background medicine, disease severity, comparator and definitions of clinical, endoscopic and histological remission. Small or incompletely blinded studies cannot support a general response rate or comparison with approved biologics. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational ulcerative-colitis cell procedures can involve separate charges for assessment, endoscopy, laboratory testing, repeat administration, monitoring, travel and complication care. Prices do not indicate regulatory approval or advantage over established medicines. Patients should request an itemised written quote and verify sponsor, insurer and patient responsibilities. Evidence-based IBD treatment and timely surgical assessment must not be delayed.

Are stem cells approved for ulcerative colitis?

Cell therapy for Ulcerative Colitis may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Will I stop biologics?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

How is it delivered?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Ulcerative Colitis programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Ulcerative Colitis (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Ulcerative Colitis overview · Ulcerative Colitis cost →